Recall Issued for Defective Blood Glucose Monitoring Systems
It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.
The FDA has announced a Class II recall for certain models of blood glucose monitoring systems due to a potential risk of inaccurate readings. According to the agency, the affected devices may return falsely low or high readings, which could lead to inappropriate treatment decisions and pose a risk to patient health.
Consumers who own the recalled devices are advised to stop using them immediately and follow the manufacturer's instructions for returning or disposing of the products. Healthcare providers are also being notified to inform patients who may be using the affected devices. No injuries or deaths have been reported, but the FDA is taking proactive measures to protect public health.
The recall affects specific models and lot numbers, which can be found on the FDA's website. Patients who are unsure about their device or have questions about alternative testing methods should consult their healthcare provider.
Media Contact
Danny Williamson
Wellington-Dufferin-Guelph Public Health
1-800-265-7293 ext. 4376